Dimos Gidaris

Dimos Gidaris

Auto-generated profile, based on publicly available information

Dimos Gidaris

Arsitotle University of Thessaloniki, 1st Paediatric Department, Thessaloniki, Greece & University of Nicosia Medical School

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2014 in Respirology
Verified
Journal Article
Closed access
PDF file
DGDimos Gidaris
Dimos Gidaris
DUDon Urquhart
Don Urquhart
MAMichael B. Anthracopoulos
Michael B. Anthracopoulos

1 May 2021 in Hypertension
Verified
Journal Article
Open access
PDF file
Stella V. StabouliStella V. Stabouli
Stella V. Stabouli
KCKaterina Chrysaidou
Katerina Chrysaidou
ACAthanasia Chainoglou
Athanasia Chainoglou
DGDimos Gidaris
Dimos Gidaris
VKVasilios Kotsis
Vasilios Kotsis
DZDimitrios Zafeiriou
Dimitrios Zafeiriou
Observational studies show that serum uric acid levels associate with cardiometabolic risk factors and subclinical target organ damage. The aim of the present study is to investigate the association of traditional cardiometabolic risk factors and uric acid with the executive performance in children and adolescents. Ninety-nine children and adolescents aged 5 to 18 years referred for assessment of primary hypertension were included. Traditional cardiometabolic risk factors, uric acid, and ambulatory blood pressure parameters were assessed. Executive performance was assessed by the validated Behavior Rating Inventory of Executive Function parent questionnaire. Serum uric acid correlated with cardiometabolic parameters, daytime and nighttime systolic blood pressure. High uric acid levels and ambulatory hypertension were associated with behavior regulation independently of other cardiometabolic risk factors or presence of metabolic syndrome. Participants with combined hypertension and high uric acid levels presented the lowest behavior regulation performance. Children with high uric acid had worse behavior regulation indices T scores with estimated marginal means 56.47 (95% CI, 51.68–61.27) compared with 49.22 (95% CI, 45.91–52.53) in those with low uric acid levels ( P =0.023, adjusted for age, sex, nighttime systolic blood pressure, daytime and nighttime heart rate). Mediation analysis showed that part of the effect of high uric acid levels on behavior regulation was mediated by nighttime systolic blood pressure. In conclusion, we found a positive association of serum uric acid with worse executive performance in children at risk for primary hypertension. Extending these cross-sectional findings with longitudinal studies may determine whether high uric acid levels increases the risk of cognitive decline in youth.

1 June 2017 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
PDF file
SSS. Stabouli
S. Stabouli
EPE. Papadimitriou
E. Papadimitriou
DGD. Gidaris
D. Gidaris
APA. Petralias
A. Petralias
NPN. Printza
N. Printza
DZD. Zafeiriou
D. Zafeiriou

7 August 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
EFEirini-Sofia Frima
Eirini-Sofia Frima
ITIlias Theodorakopoulos
Ilias Theodorakopoulos
DGDimos Gidaris
Dimos Gidaris
NKNikolaos Karantaglis
Nikolaos Karantaglis
GCGrigorios Chatziparasidis
Grigorios Chatziparasidis
Sotirios FouzasSotirios Fouzas
Sotirios Fouzas
Background: Variability analysis of peak expiratory flow (PEF) and forced expiratory volume at 1 second (FEV1) has been used in research to predict exacerbations in adults with asthma. However, there is a paucity of data regarding PEF and FEV1 variability in healthy children and adolescents and those with asthma. Objective: The objective of this study is the assessment of PEF and FEV1 variability in (1) healthy children and adolescents, to define the normal daily fluctuation of PEF and FEV1 and the parameters that may influence it, and (2) children and adolescents with asthma, to explore the differences from healthy subjects and reveal any specific variability changes prior to exacerbation. Methods: The study will include 100 healthy children and adolescents aged 6-18 years (assessment of normal PEF and FEV1 variability) and 100 children and adolescents of the same age with diagnosed asthma (assessment of PEF and FEV1 variability in subjects with asthma). PEF and FEV1 measurements will be performed using an ultraportable spirometer (Spirobank Smart; MIR Medical International Research) capable of smartphone connection. Measurements will be performed twice a day between 7 AM and 9 AM and between 7 PM and 9 PM and will be dispatched via email to a central database for a period of 3 months. PEF and FEV1 variability will be assessed by detrended fluctuation and sample entropy analysis, aiming to define the normal pattern (healthy controls) and to detect and quantify any deviations among individuals with asthma. The anticipated duration of the study is 24 months. Results: The study is funded by the “C. Caratheodory” Programme of the University of Patras, Greece (PN 47014/24.9.2018). It was approved by the Ethics Committee (decision 218/19-03-2019) and the Scientific Board (decision 329/02-04-2019) of the University Hospital of Patras, Greece. Patient recruitment started in January 2020, and as of June 2020, 100 healthy children have been enrolled (74 of them have completed the measurements). The anticipated duration of the study is 24 months. The first part of the study (assessment of lung function variability in healthy children and adolescents) will be completed in August 2020, and the results will be available for publication by October 2020. Conclusions: Healthy children and adolescents may present normal short- and long-term fluctuations in lung function; the pattern of this variability may be influenced by age, sex, and environmental conditions. Significant lung function variability may also be present in children and adolescents with asthma, but the patterns may differ from those observed in healthy children and adolescents. Such data would improve our understanding regarding the chronobiology of asthma and permit the development of integrated tools for assessing the level of control and risk of future exacerbations. Trial Registration: ClinicalTrials.gov NCT04163146; https://clinicaltrials.gov/ct2/show/NCT04163146 International Registered Report Identifier (IRRID): DERR1-10.2196/20350

1 January 2013 in Frontiers in Bioscience-Elite
Verified
Journal Article
Closed access
DGDimos Gidaris
Dimos Gidaris
SCSteve Cunningham
Steve Cunningham
Wheeze is both a symptom to parents (reported as noisy breathing) and a sign to clinical staff – with very differing perspectives between parents and clinicians on what constitutes “wheeze”. The purpose of this article is to consider these differences of understanding from the perspective of different stakeholders so that nobody is “lost in translation”. Misunderstandings may lead to epidemiologic and treatment faults. Every effort should be made to educate parents and improve their communications with clinicians.

1 April 2010
Verified
Journal Article
Closed access
DGD Gidaris
D Gidaris
FKF Kanakoudi-Tsakalidou
F Kanakoudi-Tsakalidou
DPD Papakosta
D Papakosta
VTV Tzimouli
V Tzimouli
ATA Taparkou
A Taparkou
ITI Tsanakas
I Tsanakas